PubRank

Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk (FOURIER)

Clinical Trial ID NCT01764633

PubWeight™ 24.36‹?›

🔗 Visit the ClinicalTrials.gov page for NCT01764633

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease. N Engl J Med 2017 5.08
2 Statin-associated muscle symptoms: impact on statin therapy-European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management. Eur Heart J 2015 1.92
3 Residual macrovascular risk in 2013: what have we learned? Cardiovasc Diabetol 2014 1.20
4 Safety and efficacy of anti-PCSK9 antibodies: a meta-analysis of 25 randomized, controlled trials. BMC Med 2015 1.07
5 Lipids, blood pressure and kidney update 2015. Lipids Health Dis 2015 1.00
6 The biology of PCSK9 from the endoplasmic reticulum to lysosomes: new and emerging therapeutics to control low-density lipoprotein cholesterol. Drug Des Devel Ther 2013 0.94
7 PCSK9 inhibition-mediated reduction in Lp(a) with evolocumab: an analysis of 10 clinical trials and the LDL receptor's role. J Lipid Res 2016 0.88
8 Profile of evolocumab and its potential in the treatment of hyperlipidemia. Drug Des Devel Ther 2015 0.85
9 Clinical Update: Cardiovascular Disease in Diabetes Mellitus: Atherosclerotic Cardiovascular Disease and Heart Failure in Type 2 Diabetes Mellitus - Mechanisms, Management, and Clinical Considerations. Circulation 2016 0.84
10 Cost-Effectiveness of LDL-C Lowering With Evolocumab in Patients With High Cardiovascular Risk in the United States. Clin Cardiol 2016 0.83
11 Nonstatin Low-Density Lipoprotein-Lowering Therapy and Cardiovascular Risk Reduction-Statement From ATVB Council. Arterioscler Thromb Vasc Biol 2015 0.83
12 Management of patients with familial hypercholesterolaemia. Nat Rev Cardiol 2015 0.83
13 New developments in atherosclerosis: clinical potential of PCSK9 inhibition. Vasc Health Risk Manag 2015 0.83
14 The year in cardiology 2015: prevention. Eur Heart J 2016 0.79
15 PCSK9 inhibitors in the prevention of cardiovascular disease. J Thromb Thrombolysis 2016 0.79
16 PCSK9 inhibition: the way forward in the treatment of dyslipidemia. BMC Med 2015 0.79
17 Systematic review of published Phase 3 data on anti-PCSK9 monoclonal antibodies in patients with hypercholesterolaemia. Br J Clin Pharmacol 2016 0.78
18 Evolving targets for lipid-modifying therapy. EMBO Mol Med 2014 0.78
19 Clinical efficacy and safety of evolocumab for low-density lipoprotein cholesterol reduction. Vasc Health Risk Manag 2016 0.77
20 New Era of Lipid-Lowering Drugs. Pharmacol Rev 2016 0.77
21 PCSK9 inhibition in the management of hyperlipidemia: focus on evolocumab. Vasc Health Risk Manag 2016 0.77
22 Safety and efficacy of LY3015014, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 (PCSK9): a randomized, placebo-controlled Phase 2 study. Eur Heart J 2016 0.76
23 Nutraceutical therapies for atherosclerosis. Nat Rev Cardiol 2016 0.76
24 Effect of Evolocumab in Patients With Prior Percutaneous Coronary Intervention. Circ Cardiovasc Interv 2022 0.75
25 Evolocumab lowers LDL-C safely and effectively when self-administered in the at-home setting. Springerplus 2016 0.75
26 Harnessing publicly available genetic data to prioritize lipid modifying therapeutic targets for prevention of coronary heart disease based on dysglycemic risk. Hum Genet 2016 0.75
27 The use of surrogate endpoints in regulating medicines for cardio-renal disease: opinions of stakeholders. PLoS One 2014 0.75
28 Cost-effectiveness of Evolocumab Therapy for Reducing Cardiovascular Events in Patients With Atherosclerotic Cardiovascular Disease. JAMA Cardiol 2017 0.75
29 Management of Hypercholesterolemia, Appropriateness of Therapeutic Approaches and New Drugs in Patients with High Cardiovascular Risk. High Blood Press Cardiovasc Prev 2016 0.75
Next 100